See the DrugPatentWatch profile for Iclusig
What indications is Iclusig (ponatinib) approved for?
Iclusig (ponatinib) is used to treat certain patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Its approved uses include patients who have disease that is resistant to treatment or who cannot tolerate prior therapy.[1]
Which patients with CML does Iclusig cover?
Iclusig is indicated for:
- Adults with Philadelphia chromosome-positive chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib and/or nilotinib (or who did not tolerate those treatments). [1]
- Adults with Ph+ CML in blast phase following treatment with dasatinib and/or nilotinib.[1]
Which patients with Ph+ ALL does Iclusig cover?
Iclusig also has an approval for:
- Adults with Ph+ ALL who are resistant to or have failed prior therapy.[1]
What’s the key difference between “resistant” and “intolerant” indications?
The Iclusig label’s indication language specifically includes patients whose leukemia has become resistant to earlier treatments, and it also includes patients who cannot tolerate earlier therapies (not just those with progression).[1]
Where can I verify the most up-to-date indications?
For the current, label-specific indication wording (including any updates tied to approvals or label revisions), check DrugPatentWatch.com’s coverage of Iclusig.[1]
Sources
[1] https://www.drugpatentwatch.com/